Harvard Apparatus Regenerative Technology
147 articles about Harvard Apparatus Regenerative Technology
-
Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics
6/15/2022
Biostage, Inc. announced today the publication of a paper in the peer-reviewed Journal of Biomechanics, describing a study investigating the mechanical strength of regenerated esophageal tissues.
-
Biostage Reports Q1 2022 Financial Results and Corporate Highlights
5/16/2022
Biostage, Inc. announced its financial results for the three months ended March 31, 2022, and highlighted recent events.
-
Biostage Announces $5.1 Million Financing to Advance Clinical Trial
5/13/2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), today announced that it has raised approximately $5.1 million from new and existing investors in a private placement of its shares.
-
Biostage Schedules Conference Call and Webcast for Q1 2022 Results
5/10/2022
Biostage, Inc. announced that it will release Q1 2022 financial results on May. 16th and host a conference call May.
-
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus
4/11/2022
Biostage, Inc. announced that the U.S. Patent and Trademark Office has granted a new patent that extends its key intellectual property to cover regeneration and repair of the bronchus due to cancer, injury or birth defects.
-
Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results
4/1/2022
Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results.
-
Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results
3/30/2022
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), today announced that it will be hosting a conference call to discuss fourth quarter and full year financial results.
-
Biostage Announces "Meet the Founder, New Chairman and Interim CEO" Webinar
1/25/2022
Biostage, Inc. announced that it will be hosting a webinar to allow investors to meet its new Interim CEO, David Green.
-
New Paper Shows Biostage's Esophageal Implant Regenerates the Esophagus in Piglets
1/10/2022
Biostage, Inc., a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, announced the publication of paper establishing the basis for using its product to treat birth defects in the esophagus in babies.
-
Biostage Hires David Green as Chief Executive Officer
11/30/2021
Biostage, Inc., a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, announced it has hired David Green as its Chief Executive Officer and appointed Mr. Green as Chairman of the Board of Directors.
-
Biostage Reports Q3 2021 Financial Results
11/15/2021
Biostage, Inc., a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, announced its financial results for the three and nine months ended September 30, 2021.
-
Biostage™ Appoints Jerry He to Board of Directors and Completes Private Placement of $2.6 Million to Continue Its Clinical Transition
9/8/2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing novel organ regeneration technology based its patented Cellframe™ and Cellspan™ technology, today announced the appointment of Jerry He as an independent director to its Board of Directors, adding strength in the areas of business innovation, strategy and finance.
-
Biostage Reports Q2 2021 Financial Results
8/13/2021
Biostage, Inc., a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, announced its financial results for the three and six months ended June 30, 2021.
-
Biostage Reports Q1 2021 Financial Results
5/24/2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellframe™ and Cellspan™ technology, today announced its financial results for the three months ended March 31, 2021 .
-
Biostage Reports 2020 Financial Results and Appointment of Interim Vice President of Finance
4/13/2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing next-generation bioengineered esophageal implants, today announced its financial results for the three and twelve months ended December 31, 2020.
-
Biostage Strengthens Board of Directors with Appointment of Herman Sanchez
1/25/2021
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants, today announced that it appointed Herman Sanchez as an independent director to its Board of Directors.
-
Biostage Reports Third Quarter 2020 Financial Results
11/13/2020
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspan™ technology for the treatment of esophageal atresia and esophageal disease, today announced its financial results for the three and nine months ended September 30, 2020.
-
Biostage Reports Second Quarter 2020 Financial Results
8/13/2020
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspan™ technology for the treatment of esophageal atresia and esophageal disease, today announced its financial results for the three and six months ended Jun
-
Biostage Reports First Quarter 2020 Financial Results
5/14/2020
Biostage, Inc., a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspan™ technology, announced its financial results for the three months ended March 31, 2020.
-
Biostage Reports 2019 Financial Results
3/27/2020
("Biostage" or the "Company"), a biotechnology company developing next-generation esophageal implants, today announced its financial results for the three and twelve months ended December 31, 2019 .